1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Tiziano Frateschi
Tiziano Frateschi
Articles (2519)  | Author's Website |

5 Health Care Stocks Trading With Low Price-Earnings Ratios

Genesis tops the list

As of July 14, the GuruFocus All-in-One Screener, a Premium feature, found that the following companies in the health care sector have low price-earnings ratios and have been bought by gurus. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

Genesis

With a market cap of $118 million, Genesis Healthcare Inc. (GEN) has a price-earnings ratio of 1.45. According to the DCF calculator, the stock has a fair value of $5.24 while trading at $0.71.

94f665f14014070f4bd1eb0747bce21c.png

The stock has lost 42.28% over the last 12 months and is now 61.83% below the 52-week high and 22.41% above the 52-week low.

The U.S. post-acute care provider has a GuruFocus profitability rating of 4 out of 10. The return on assets of 0.32% is underperforming 54% of companies in the healthcare providers and services industry. Its financial strength is rated 2 out of 10. The cash-debt ratio of 0.01 is below the industry median of 0.55.

The companys largest guru shareholder is Jim Simons (Trades, Portfolio) Renaissance Technologies with 2.63% of outstanding shares.

Five Star

With a $115 million market cap, Five Star Senior Living Inc. (FVE) is trading with a price-earnings ratio of 1.84. According to the DCF calculator, the stock has a fair value of $21.30 while trading at $3.66.

2f14b680e2be03e3fe6505f3fa6e0d1b.png

The share price has declined 20.69% over the past 12 months and is now 51.20% below the 52-week high and 71.83% above the 52-week low.

The owner of medical care facilities has a GuruFocus profitability rating of 3 out of 10. The return on equity of -3.12% and return on assets of -0.4% are underperforming 69% of companies in the healthcare providers and services industry. Its financial strength is rated 8 out of 10. The cash-debt ratio of 1.92 is above the industry median of 0.55.

Simons firm is the companys largest guru shareholder with 0.69% of outstanding shares.

Orgenesis

With a market cap of $124 million, Orgenesis Inc. (ORGS) is trading with a price-earnings ratio of 1.87 and a price-book ratio of 1.16.

2d6382cd0789c354015139a2b483fa04.png

Shares have increased 34.96% over the last 12 months and are now 31.22% below the 52-week high and 140% above the 52-week low.

The biopharmaceutical company has a GuruFocus profitability rank of 1 out of 10. The company's return on equity of 194.89% and return on assets of 63.74% are outperforming 99% of competitors in the biotechnology industry. The cash-debt ratio of 8.96 is above the industry median of 8.32.

Simons firm is the companys largest guru shareholder with 0.17% of outstanding shares.

Palatin Technologies

Palatin Technologies Inc. (PTN) has a market cap of $114 million and is trading with a price-earnings ratio of 2.76. According to the DCF calculator, the stock has a fair value of $1.93 while trading at $0.50.

294f741dcc86b84a9da10daf41772f48.png

Shares have declined 46.93% over the last 12 months and are now trading 71.91% below the 52-week high and 38.89% above the 52-week low.

The biotechnology company has a GuruFocus profitability rating of 1 out of 10. The return on equity of 56.5% and return on assets of 53.71% are outperforming 99% of companies in the biotechnology industry. Its financial strength is rated 8 out of 10. The company has no debt.

With 0.04% of outstanding shares, Pioneer Investments (Trades, Portfolio) is the companys largest guru shareholder.

Lexicon

Lexicon Pharmaceuticals Inc. (LXRX) has a market cap of $203 million. Its shares are trading with a price-earnings ratio of 3.08. According to the DCF calculator, the stock has a fair value of $6.64 while trading at $1.92.

7b467bc071836b27cab0e26bfeab57d0.png

Shares have declined 69.35% over the past 12 months and are currently trading 73.87% below the 52-week high and 68.14% above the 52-week low.

The company has a GuruFocus profitability rating of 3 out of 10. The return on equity of 188.74% and return on assets of 24.74% are outperforming 99% of competitors in the biotechnology industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 1.02 is below the industry median of 8.32.

The companys largest guru shareholder is Renaissance Technologies with 1.56% of outstanding shares, followed by Barrow, Hanley, Mewhinney & Strauss with 0.11% and Pioneer Investments (Trades, Portfolio) with 0.04%.

Disclosure: I do not own any stocks mentioned.

Read more here:

Not a Premium Member of GuruFocus? Sign up for afree 7-day trial here.

About the author:

Tiziano Frateschi
You can read about me on www.theextraincome.info, which gives suggestions on position trading.

Visit Tiziano Frateschi's Website


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by Tiziano Frateschi


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)